Nutriband Inc. Secures U.S. Patent for Innovative Abuse-Deterrent Transdermal Technology
TL;DR
Nutriband's new U.S. patent for its Aversa technology offers a competitive edge in the abuse-deterrent transdermal market, potentially capturing significant sales with Aversa Fentanyl.
The U.S. patent No. 12,318,492 details Nutriband's method to prevent abuse and misuse in transdermal systems, enhancing its Aversa technology's market protection.
Nutriband's Aversa technology aims to reduce drug abuse and accidental exposure, contributing to safer medication practices and better public health outcomes.
Discover how Nutriband's patented Aversa technology is revolutionizing transdermal patches to combat drug abuse, with Aversa Fentanyl leading the charge.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc. (NASDAQ: NTRB) has achieved a milestone in the pharmaceutical industry by securing U.S. patent No. 12,318,492 for its 'Abuse and Misuse Deterrent Transdermal Systems.' This patent, awarded on June 3, 2025, fortifies the company's intellectual property rights over its Aversa(TM) technology, designed to mitigate the risks of drug abuse, misuse, diversion, and accidental exposure. The technology is pivotal in the development of Nutriband's lead product, Aversa Fentanyl, which aspires to be the first abuse-deterrent fentanyl patch available in the market, with potential U.S. sales ranging between $80 million and $200 million.
The significance of this patent extends beyond corporate achievement; it represents a critical advancement in public health. The opioid crisis has underscored the urgent need for innovative solutions to prevent drug abuse. Nutriband's Aversa(TM) technology, by making transdermal patches less susceptible to abuse, could play a vital role in curbing the epidemic, offering a safer alternative for patients requiring potent pain management solutions. This development not only enhances Nutriband's market position but also contributes to the broader effort to address one of the most pressing health challenges of our time.
Curated from InvestorBrandNetwork (IBN)
